A meta-analysis of controlled clinical trials comparing peginterferon-α plus nucleos(t)ide analogs versus peginterferon-α monotherapy for HBsAg clearance or seroconversion in patients with chronic hepatitis B
PEG-IFN-α promotes HBsAg clearance and seroconversion. Combination therapy with PEG-IFN-α plus NAs yields higher short-term clearance than monotherapy; however, sustained benefits appear to require prolonged treatment.
Authors
- Xuebin Cai
- Ying Wang (ORCID: https://orcid.org/0000-0002-9636-6300)
- Shuyao Zhu
- Chaochao Qin
- Zhilin Yang
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3389/fmed.2025.1716225
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00